A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.
Vanderbilt leads $12M effort to accelerate real-world impact of biomedical innovations through education, mentorship and funding for aspiring entrepreneurs